OnabotulinumtoxinA for the treatment of major depressive disorder: a phase 2 randomized, double-blind, placebo-controlled trial in adult females

This 24-week double-blind placebo-controlled multicenter randomized phase 2 trial evaluated efficacy and safety of onabotulinumtoxinA (onabotA; BOTOX) vs. placebo for major depressive disorder (MDD) [NCT02116361]. Primary endpoint was the change in Montgomery-Åsberg Depression Rating Scale (MADRS);...

Descripción completa

Detalles Bibliográficos
Autores principales: Brin, Mitchell F., Durgam, Suresh, Lum, Arlene, James, Lynn, Liu, Jeen, Thase, Michael E., Szegedi, Armin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams And Wilkins 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6903360/
https://www.ncbi.nlm.nih.gov/pubmed/31609787
http://dx.doi.org/10.1097/YIC.0000000000000290

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6903360/
https://www.ncbi.nlm.nih.gov/pubmed/31609787
http://dx.doi.org/10.1097/YIC.0000000000000290

Ejemplares similares